BOSTON, November 07, 2025--nChroma Bio, a genetic medicines company advancing in vivo delivery of innovative cargoes to overcome the limitations of existing therapies, today announced new preclinical ...
Single ascending dose data show IMC-I109V has manageable safety profile and antiviral activityIMC-I109V is a bispecific T cell receptor targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback